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Abstract
Background:  Glucocorticoids down-regulate cytokine synthesis and suppress inflammatory
responses. The glucocorticoid receptor (GR) antagonist RU486 may exacerbate the inflammatory
response, and concerns over this exacerbation have limited the development and clinical use of GR
antagonists in the treatment of diabetes and depression. We investigated the effects of RU486 on
serum cytokines in db/db mice and on lipopolysaccharide (LPS)-induced circulating TNFα levels in
both normal AKR mice and diet-induced obese (DIO) C57BL/6 mice.
Results:  Chronic treatment of db/db mice with RU486 dose-dependently decreased blood
glucose, increased serum corticosterone and ACTH, but did not affect serum MCP-1 and IL-6
levels. LPS dose-dependently increased serum TNFα in both AKR and C57BL/6 DIO mice, along
with increased circulating corticosterone and ACTH. Pretreatment of the mice with RU486 dose-
dependently suppressed the LPS induced increases in serum TNFα and further increased serum
corticosterone.
Conclusion: RU486 at doses that were efficacious in lowering blood glucose did not exacerbate
cytokine release in these three mouse models. RU486 actually suppressed the lower dose LPS-
mediated TNFα release, possibly due to the increased release of glucocorticoids.
Background
Various clinical and pre-clinical investigations have indi-
cated that antagonists of the glucocorticoid receptor (GR)
could be useful in the treatment of diabetes [1,2] and
depression [3], but concerns about the effects of GR antag-
onists on the body's ability to regulate inflammatory
responses [4] have hampered development of GR antago-
nists for these indications.
Activation of the GR with endogenous glucocorticoids
(GCs) is the body's primary method for suppression of the
inflammatory response [5]. In fact, host survival in bacte-
rial and viral infection is dependent upon the proper con-
trol of the inflammatory response through timely
activation of the hypothalamic-pituitary-adrenal (HPA)
axis for the production of cortisol, the primary glucocorti-
coid in humans [6]. The innate immune system stimulates
the controlled production and timely release of GCs to
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prevent an overly strong response to an ongoing localized
inflammatory process [7]. Disruption of this response due
to exhaustion of the adrenal cortex results in septic shock.
In the treatment of septic shock, low doses of GCs have
therapeutic effects by correcting adrenal cortex exhaus-
tion, exerting appropriate anti-inflammatory properties,
and enhancing endogenous catecholamine effects [8].
Antagonism of the GR by mifepristone (RU486), pharma-
cologically classified as both a progesterone and glucocor-
ticoid antagonist [9], has been shown to ameliorate
metabolic parameters in rodent model of type 2 diabetes
(T2D) [10]. However, the potential for GR antagonists to
exacerbate inflammation is a major concern limiting the
use of GR antagonists for the treatment of diabetes,
depression, and other conditions. It was postulated that
RU486 could exacerbate the inflammatory response and
lead to septic shock through inhibition of the body's
mechanism for controlling inflammation by virtue of its
ability to block the GR in phagocytes located at the site of
invading bacteria [11], by disrupting the negative pituitary
feedback, and by deteriorating adrenal cortex exhaustion
[12]. In experimental animals, blockade of the GR by
RU486 was shown to increase the mortality of endotox-
emic rats administered lipopolysaccharide, and to
increase TNFα production and toxicity [13]. There have
also been reports of deaths from septic shock in patients
using RU486 as an abortifacient [14-16].
The association between use of RU486 and deaths from
septic shock has only been reported under the condition
of abortion (via progesterone receptor antagonism). No
causal relationship has been established between RU486
and septic shock. The use of RU486 in Cushing's syn-
drome [17-19], breast cancer [20], endometriosis [21],
and leiomyoma [22] has not been associated with septic
shock, although all the applications are also based on
either progesterone receptor antagonism or GR antago-
nism. The incidence of septic shock may depend on dis-
ease conditions and RU486 dosages.
In the effort to develop GR antagonists for chronic treat-
ment of diabetes, we desired to investigate the acute and
chronic effect of GR antagonist on the inflammatory
responses in animals under both normal and disease con-
ditions at doses that are efficacious in the treatment of
T2D. Therefore, the current study investigated the effect of
acute and chronic use of RU486 on inflammatory
cytokines in various mouse models, including normal
AKR mice and two rodent models of T2D, the monogenic
leptin receptor defect db/db mice and the diet-induced
obese (DIO) C57BL/6 mice.
Results
RU486 dose-dependently decreased blood glucose but did 
not affect serum cytokines in db/db mice
At an age of 11–12 weeks, db/db mice had significantly
higher levels of blood glucose, HbA1c, serum insulin,
total cholesterol, triglycerides, and interleukin-6 (IL-6),
and similar level of serum monocyte chemoattractant pro-
tein-1 (MCP-1) compared with the C57BL/6J lean litter
mates (Fig 1 and Table 1). Serum tumor necrosis factor
alpha (TNFα) and interleukin-1beta (IL-1β) were below
quantifiable levels (BQL) in both db/db mice and their
lean litter mates. The db/db mice also had significantly
higher levels of serum corticosterone, similar levels of
adrenocorticotropic hormone (ACTH), and higher expres-
sion levels of hepatic glucogenesis enzyme phosphe-
nolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6Pase) genes compared with the C57BL/
6J lean litter mates (Fig 1 and Table 1).
Treatment of the db/db mice at an age 10–12 weeks with
GR antagonist RU486 for 10 days significantly decreased
postprandial blood glucose in a dose- and time-depend-
ent manner (Fig 1a), confirming the glucose lowering
effect of RU486 and establishing the efficacious dose.
RU486 down-regulated hepatic PEPCK expression levels
(Fig 1b), and trended to lower G6Pase (Fig 1c) gene
expression, and increased serum levels of corticosterone
(Fig 1e) and ACTH (Fig 1f) in db/db mice. RU486 did not
affect serum MCP-1 and IL-6 levels in the db/db mice (Fig
1d).
RU486 decreased LPS-induced serum TNFα in normal AKR 
mice along with an increase in serum corticosterone
As shown in Fig 2, ninety minutes after LPS intraperito-
neal (ip) injection, serum TNFα and IL-6 levels were
increased in a dose- and time-dependent manner. The LPS
doses of 0.1 and 0.5 mg/kg were the at the lower part of
the dose-response curve for TNFα induction (Fig 2a), indi-
cating that these doses should be far from the exhausting
capacity for TNFα production. The 90 minute exposure
time was also in the middle of TNFα release curve (Fig
2b). The LPS-induced IL-6 production, which was much
more sensitive than TNFα production, reached a maximal
level at an LPS dose of 0.5 mg/kg 90 minutes after expo-
sure (Fig 2c and Fig 2d). In the subsequent studies of LPS
challenge in AKR mice, the middle LPS doses of 0.1 and
0.5 mg/kg, an exposure time of 90 minutes, and the
parameter of TNFα production were employed.
While LPS doses of 0.1 and 0.5 mg/kg increased serum
TNFα to different levels, oral RU486 significantly inhib-
ited both LPS 0.1 and 0.5 mg/kg-induced increase in
serum TNFα. This inhibition trended to be dose-depend-
ent and is opposite to the proposed pro-inflammation
effects of RU486 (Fig 3a and Fig 3d). Both LPS 0.1 and 0.5BMC Pharmacology 2008, 8:7 http://www.biomedcentral.com/1471-2210/8/7
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mg/kg resulted in significantly higher serum corticoster-
one (Fig 3b and Fig 3e) and ACTH (Fig 3c and 3f). Pre-
treatment with RU486 further increased serum corticos-
terone in these animals, but did not affect the LPS-ele-
vated ACTH (Fig 3c and Fig 3f).
RU486 decreased low dose LPS-induced serum TNFα in 
C57BL/6 DIO mice along with an increase in serum 
corticosterone, but did not affect the high dose LPS-
mediated changes
After 12–13 weeks on cafeteria diet, C57BL/6 mice had a
phenotype of higher body weight, serum glucose and
insulin, dyslipidemia, and had higher serum TNFα and
similar IL-6 (Table 2) compared to normal diet controls.
Acute LPS challenge in C57BL/6 DIO mice markedly
increased serum TNFα in a dose-dependent manner (Fig
4), which was more pronounced than that in normal diet
controls (with LPS 20 mg/kg, 12852 ± 1185 pg/ml vs
6494 ± 1655 pg/ml in normal diet controls, p < 0.05). Pre-
treatment with RU486 decreased the low dose 0.1 mg/kg
LPS-induced serum TNFα, but did not affect the higher
dose 0.5 mg/kg LPS-elevated serum TNFα (Fig 4a). LPS
increased serum corticosterone in the C57BL/6 DIO mice
(Fig 4b). Pretreatment with RU486 further increased the
LPS (0.1 and 0.5 mg/kg)-elevated serum corticosterone
but did not affect serum ACTH (Fig 4b and 4c).
Effects of RU486 (oral, BID, 10 days) on blood glucose (a), liver genes of PEPCK (b) and G6Pase (c), and serum IL-6 and MCP- 1 (d), corticosterone (e), and ACTH (f) in db/db mice Figure 1
Effects of RU486 (oral, BID, 10 days) on blood glucose (a), liver genes of PEPCK (b) and G6Pase (c), and serum 
IL-6 and MCP-1 (d), corticosterone (e), and ACTH (f) in db/db mice. Lean-V: lean litter mates treated with vehicle. 
db/db-V: db/db mice treated with Vehicle. db/db-RU 2.5: db/db mice treated with RU486 2.5 mg/kg. db/db-RU 7: db/db mice 
treated with RU486 7 mg/kg. db/db-RU 20: db/db mice treated with RU486 20 mg/kg. db/db-RU 50: db/db mice treated with 
RU486 50 mg/kg. Serum corticosterone and ACTH were presented as ng/ml. PEPCK and G6Pase were normalized with cyclo-
philin.
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In another experiment, C57BL/6 DIO mice were ip
injected with LPS at the dose of 20 mg/kg. This high dose
of LPS led to inactivity and diarrhea in mice, an exagger-
ated increase in serum TNFα, and moderate increases in
serum corticosterone and ACTH (Fig 4d–f). Pretreatment
with RU486 in the C57BL/6 DIO mice did not affect the
high dose LPS-mediated changes in serum TNFα, corticos-
terone, and ACTH (Fig 4d–f).
Discussion
The current study demonstrated that chronic treatment
with GR antagonist RU486 for 10 days dose-dependently
decreased postprandial blood glucose, increased serum
corticosterone and ACTH, and did not affect serum MCP-
1 and IL-6, in db/db mice. Injection of LPS increased cir-
culating TNFα, corticosterone, and ACTH in both normal
AKR mice and C57BL/6 DIO mice. RU486 suppressed the
lower dose LPS-elevated serum TNFα in both normal AKR
mice and C57BL/6 DIO mice, and further increased circu-
lating corticosterone. The RU486 pretreatment did not
affect the high dose LPS (20 mg/kg)-mediated changes in
serum TNFα and corticosterone. It is worth noting that the
data sets from each strain/model examined were not
exactly the same in current studies. But all the studies
showed that RU486 either decreased cytokine along with
increased corticosterone, or did not affect cytokine along
with or without change in corticosterone. Thus RU486, at
doses which are efficacious on glucose lowering, did not
show any exacerbating effect on cytokine production in
both chronic and acute settings, and RU486 could actu-
ally suppress the lower dose LPS-mediated TNFα release,
possibly due to the increased release of GCs. The interpre-
tation of the data sets were discussed below.
Although GR antagonism has been shown to inhibit glu-
coneogenesis and lower glucose in humans [1] and in
rodent model of T2D [23], the concern about GR antago-
Table 1: Phenotype of db/db mice
Lean litter mates db/db mice
Body weight (g) 24.1 ± 0.6 39.8 ± 0.5**
Blood
Glucose (mg/dL) 120.1 ± 4.6 319.9 ± 37.5**
HbA1c (%) 3.2 ± 0.2 5.4 ± 0.6**
Serum
Insulin (ng/ml) 0.3 ± 0.1 12.6 ± 2.9**
Total cholesterol (mg/dL) 73.8 ± 1.8 127 ± 3.2**
Triglycerides (mg/dL) 125.4 ± 15.8 200.9 ± 19.5**
IL-6 (pg/ml) 40.1 ± 4.5 61.8 ± 8.6*
MCP-1 (pg/ml) 34.4 ± 5.0 32.4 ± 1.0
TNFα BQL BQL
IL-1β BQL BQL
Corticosterone (ng/ml) 45.7 ± 17.8 615 ± 36.4**
ACTH (ng/ml) 2.9 ± 0.4 2.4 ± 0.5
* p < 0.05 vs lean litter mates. **p < 0.01 vs lean litter mates.
BQL: Below quantifiable level.
LPS induced dose-dependent TNFα (a) and IL-6 (c) production and LPS induced time-dependent TNFα (b) and IL-6 (d) pro- duction in AKR mice Figure 2
LPS induced dose-dependent TNFα (a) and IL-6 (c) production and LPS induced time-dependent TNFα (b) 
and IL-6 (d) production in AKR mice. LPS exposure time was 90 minutes in (a) and (c). LPS dose in (b) and (d) was 0.5 mg/
kg.
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nists on pro-inflammation hampers the long-term treat-
ment with GR antagonists in T2D. The current study used
db/db mice to determine the effect of chronic RU486 on
circulating cytokines, which is a simulative study to mimic
drug use in patients with T2D. The authors found that
RU486 dose-dependently decreased postprandial blood
glucose, increased serum corticosterone and ACTH, but
did not affect serum MCP-1 and IL-6, although the basal
IL-6 was higher in db/db mice than in the lean littermate
controls. The significantly higher level of IL-6 in the db/db
mice is consistent with a state of chronic low-grade
inflammation. The changes in glucose, corticosterone,
and ACTH in RU486-treated db/db mice were consistent
with relevant literature reports, and confirmed the effica-
cious drug exposure (measured serum drug level 2–3
hours after last dose: 14 ± 3, 33 ± 3, 273 ± 17, and 719 ±
57 nM, respectively at doses of 2.5, 7, 20, and 50 mg/kg).
These findings suggest that RU486 did not further
enhance inflammation in this mouse model of T2D with
low grade inflammation. The dose-effect curves of RU486
on glucose, corticosterone, and ACTH were used to decide
the RU486 doses 4–100 mg/kg used in the subsequent
acute studies.
In the treatment of septic shock, low doses of glucocorti-
coids have anti-inflammatory properties. GR antagonists
might block the anti-inflammatory effect of endogenous
cortisol, and deteriorate inflammation. Excessive LPS
release from the bacterial wall into the circulation is the
primary pathogenic process of septic shock [24]. To eval-
uate the effect of RU486 under the condition of septic
shock, an LPS-challenge model was used in the current
studies. We found that in normal AKR mice, LPS dose-
dependently increased serum TNFα and caused increases
in corticosterone and ACTH. Since LPS-increased circulat-
ing TNFα and other circulating cytokines can trigger the
Effects of acute RU486 treatment on LPS (0.1 and 0.5 mg/kg)-induced changes in serum TNFα (a and d), corticosterone (b and  e), and ACTH (c and f) in normal AKR mice Figure 3
Effects of acute RU486 treatment on LPS (0.1 and 0.5 mg/kg)-induced changes in serum TNFα (a and d), corti-
costerone (b and e), and ACTH (c and f) in normal AKR mice. RU486 was oral gavaged 30 minutes prior to ip LPS. 
LPS exposure time was 90 minutes.
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neural circuits that control the HPA axis [25], the increases
in corticosterone and ACTH in response to LPS challenge
were an expected stress response of HPA axis [26]. Inter-
estingly, pretreatment with RU486 dose-dependently
decreased serum TNFα, which is contrary to the hypothe-
sis that RU486 would exacerbate inflammation. There was
also a dose-dependent increase in circulating corticoster-
one in response to RU486 treatment, which is a well
known compensatory reaction in response to the GR
antagonism. Thus the suppression of LPS-mediated TNFα
production in RU486-treated mice was most likely a con-
sequence of the increased circulating corticosterone.
Because of the compensatory increase in endogenous glu-
cocorticoids, acute GR antagonism with RU486 does not
necessarily lead to exacerbation of inflammation.
It has been reported that diet-induced obesity or/and diet-
induced insulin resistance in mice is associated with low
Effects of acute RU486 treatment on lower doses of LPS (0.1 and 0.5 mg/kg)-induced changes in serum TNFα (a), corticoster- one (b), and ACTH (c), and on high dose LPS (20 mg/kg)-induced changes in serum TNFα (d), corticosterone (e), and ACTH  (f) in C57BL/6 DIO mice Figure 4
Effects of acute RU486 treatment on lower doses of LPS (0.1 and 0.5 mg/kg)-induced changes in serum TNFα 
(a), corticosterone (b), and ACTH (c), and on high dose LPS (20 mg/kg)-induced changes in serum TNFα (d), 
corticosterone (e), and ACTH (f) in C57BL/6 DIO mice. RU486 was oral gavaged 30 minutes prior to ip LPS. LPS expo-
sure time was 90 minutes. * p < 0.05 vs no-LPS. ** p < 0.01 vs no-LPS. + p < 0.05 vs no-RU486.
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Table 2: Phenotype of C57BL/6 DIO mice
Normal diet controls DIO mice
Body weight (g) 28.7 ± 0.3 44.6 ± 0.6**
Blood
Glucose (mg/dL) 121 ± 3 160 ± 6*
HbA1c (%) 3.6 ± 0.2 3.5 ± 0.3
Serum
Glucose (mg/dL) 225 ± 15** 344 ± 22*
Insulin (ng/ml) 0.45 ± 0.06 5.07 ± 1.03**
Total cholesterol (mg/dL) 67.0 ± 3.3 223.0 ± 3.1**
Triglycerides (mg/dL) 93.0 ± 14.6 138.0 ± 9.8*
FFA (mEq/L) 0.35 ± 0.03 0.47 ± 0.02*
IL-6 (pg/ml) 191.2 ± 86.7 243.2 ± 144.7
TNFα(pg/ml) 24.0 ± 1.1 35.6 ± 2.4*
Corticosterone (ng/ml) 310 ± 30 380 ± 86
ACTH (ng/ml) 2.3 ± 0.2 3.3 ± 1.0
* p < 0.05 vs lean litter mates. **p < 0.01 vs lean littermates.BMC Pharmacology 2008, 8:7 http://www.biomedcentral.com/1471-2210/8/7
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grade inflammation, as evidenced by macrophage accu-
mulation in adipose tissue and increased serum cytokines
[27,28]. Chronic low-grade inflammation in these mice
could alter the effects of RU486 on LPS-induced TNFα
production compared to the effects in normal mice.
Therefore, we used C57BL/6 DIO mice to determine the
effects of LPS and RU486. The phenotype of the C57BL/6
DIO mice was consistent with the literature [29]. While
the LPS-induced increases in serum TNFα and corticos-
trone were similar to those in normal AKR mice, the
effects of RU486 pretreatment on the LPS-mediated
changes in C57BL/6 DIO mice were different than that in
the normal AKR mice. RU486 suppressed 0.1 mg/kg LPS-
induced TNFα production but did not affect 0.5 mg/kg
LPS-induced TNFα production, despite the fact that
RU486 further increased serum corticosterone at both LPS
doses. Thus, under these conditions, the compensatory
increase in glucocorticoids was not able to suppress LPS-
induced TNFα production.
Considering that the stress response during sepsis could
exhaust adrenal cortex, a very high dose of exogenous LPS
could mimic this state and would exhaust the endogenous
glucocorticoids. Under these conditions, RU486 may no
longer be able to cause compensatory glucocorticoid
release. Whether RU486 pretreatment exacerbates LPS-
induced TNFα production under this condition is not
known. Therefore, we used LPS 20 mg/kg in C57BL/6 DIO
mice to observe the effect of RU486 in this stressed condi-
tion. We found that this very high dose of LPS led to an
exaggerated increase in serum TNFα, but increases in
serum corticosterone and ACTH were similar to those
observed after LPS 0.1 and 0.5 mg/kg. RU486 pretreat-
ment did not affect the 20 mg/kg LPS-mediated changes
in TNFα, corticosterone, and ACTH. Despite this lack of
increase in glucocorticoids, RU486 did not enhance TNFα
production.
There are a few papers reporting GR agonist activity of
RU486 in some in vitro and in vivo systems. Nordeen et
al [30] reported that protein kinase A activators unmasked
the agonist effect of RU486 as mediating an induction of
hormone-responsive report genes. Zhang et al [31]
reported that the GR agonist activities of RU486 were
dependent on the GR levels but not on EC50 values in
COS-7 cells transfected with GR expression vector. Schulz
et al [32] reported that the RU486-induced GR agonism
was controlled by the receptor N terminus and by core-
pressor binding. All these reports indicated that RU486
may act as a GR agonist under certain conditions on cer-
tain pathways/procedures. This agonist activity of RU486
may contribute to our observation of decreasing LPS-
induced TNFα by RU486 in normal AKR mice and C57Bl/
6 DIO mice. Although the mechanism and extent of GR
agonist activities of RU486 in whole animals is not
known, the GR agonist activities of RU486 reduce the
extent of, and concerns about, potential inflammatory
exacerbation by the drug.
As demonstrated in the current studies, LPS challenge is a
strong stress to the subjects. LPS not only increases
cytokine production (such as TNFα and IL-6), but also
stimulates HPA axis and leads to increases in both serum
corticosterone and ACTH. The levels of cytokine, ACTH,
and corticosterone are considered to be the homeostatic
status under the LPS-challenge. In the HPA axis, GCs have
negative feedback effects on hypothalamus and anterior
pituitary gland. GR antagonism with RU486 blocks the
GR throughout body tissues and even blocks GCs' nega-
tive feedback receptors in the hypothalamus and anterior
pituitary gland. This blockade leads to activation of HPA,
and results in increased rate of synthesis and release of
ACTH and GCs. The current studies in AKR mice and
C57BL/6 DIO mice demonstrated that the acute RU486
pretreatment resulted in an increase only in corticosterone
but not in ACTH. This finding indicates that GCs may
have a negative feedback on the adrenal cortex, thus regu-
lating its own synthesis and release.
Although the 5 deaths of septic shock were reported to be
associated with use of RU486 [14-16], and antagonism of
the GR was hypothesized to be the primary cause [16], the
current studies in three different strains of animals with
normal and abnormal metabolism have not shown
inflammatory exacerbation by RU486 treatment. This sug-
gests, notwithstanding the species and strain differences,
that mechanisms other than, or along with, antagonism of
the GR may contribute to the inflammatory exacerbation
exhibited by RU486 in obstetric/gynecologic clinic.
RU486 also blocks progesterone receptors [33], and pro-
gesterone also demonstrates anti-inflammatory properties
[34-37]. Therefore, the septic shock associated with use of
RU486 as abortifacient may not be solely due to antago-
nism of the GR by RU486. The exact cause of these deaths
needs to be further investigated.
Conclusion
Our studies demonstrated that chronic treatment with GR
antagonist RU486 in db/db mice and acute use of RU486
in LPS-challenged normal and DIO mice did not show
any evidence of exacerbating cytokine production. These
findings suggest that the compensatory increase in circu-
lating GCs induced by RU486 treatment results in an net
anti-inflammatory effect, and suggest that the septic shock
associated with use of RU486 as an abortifacient is not
solely due to GR antagonism.BMC Pharmacology 2008, 8:7 http://www.biomedcentral.com/1471-2210/8/7
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Methods
Experimental animals
All procedures performed were in compliance with the
Animal Welfare Act and U.S. Department of Agriculture
regulations, and were approved by the GlaxoSmithKline
Animal Care and Use Committee. Male AKR mice (8–9
weeks old) were purchased from Jackson Laboratory (Bar
Harbor, ME) and were fed rodent chow Purina 5001 (PMI
Nutrition International, LLC, Brentwood, Mo). Db/db
mice (8–9 weeks old) and C57BL/6J lean litter mates (for
db/db control, 8–9 weeks old) were purchased from Jack-
son Laboratory (Bar Harbor, ME) and were fed PMI 5K67
diet (PMI Nutrition International, LLC, Brentwood, Mo).
Male C57BL/6 mice (5–6 weeks) were purchased from
Taconic (Hudson, NY) and were fed cafeteria diet (rodent
chow Purina 5001, Lard diet with 60% fat source calorie,
and condensed milk diet, Research Diets, Inc., New Bruns-
wick, NJ) for 12–13 weeks (preparing the diet-induced
obesity mice, i.e., DIO mice), or fed rodent chow Purina
5001 for normal diet controls. Animals ate and drank ad
libitum. AKR mice and db/db mice were acclimatized for 1
week before experimental procedures.
RU486 in db/db mice
Db/db mice were monogenic leptin receptor defect mice,
with a phenotype of T2D. This strain of mice was used to
simulate the effect of RU486 on T2D subjects.
Six groups of mice (n = 5~9/each group) were assigned as
follows: db/db mice treated with RU486 0 (vehicle), 2.5,
7, 20, and 50 mg/kg, BID, PO, and C57BL/6J lean litter
mates treated with vehicle 0.5% hydroxypropyl methyl-
cellulose-0.1% tween 80 10 ml/kg, BID, PO, for 10.5 days.
Postprandial blood glucose was monitored before starting
treatment and 1, 3, 6, and 10 days after treatment between
7–8 am prior to morning dosing, via tail snip (3–4 mm
from the tip) using Elite® XL Glucometer (Bayer, Tarry-
town, NY). 2–3 hours after the last dose, mice were anes-
thetized under isoflurane. Blood was collected via cardiac
stick for measuring HBA1c and obtaining serum. Liver
samples were collected for determining gene expression
levels of glucogenesis enzyme PEPCK and G6Pase. Serum
was used for measuring inflammatory parameters TNFα,
MCP-1, IL-1β, andIL-6; HPA axis parameters ACTH, and
corticosterone; and metabolic parameters glucose, insu-
lin, total cholesterol, and triglycerides.
RU486 in AKR mice acutely challenged with 
lipopolysaccharide (LPS)
AKR mice, at age 9–10 weeks old and fed ordinary rodent
diet, were normal in metabolism [38]. This strain of mice
was used to simulate the effect of RU486 on LPS-induced
cytokine release in healthy subjects.
To demonstrate the effect of LPS on serum cytokine pro-
duction, one set of AKR mice was intraperitoneally (ip)
injected with LPS 0.001–10 mg/kg (in saline), then sub-
jected to blood collection via cardiac stick under isoflu-
rane 90 minutes after LPS injection; another set of AKR
mice was ip injected with LPS 0.5 mg/kg, then subjected
to blood collection via cardiac stick under isoflurane 30,
60, 90, and 120 minutes after LPS injection. Serum sepa-
rated from the blood samples was analyzed for TNFα, IL-
6, corticosterone, and ACTH. To determine the effect of
RU486 on LPS-stimulated cytokine production in vivo,
AKR mice were orally gavaged with vehicle or RU486 5,
20, 50, or 100 mg/kg. Thirty minutes later, the mice were
ip injected with LPS 0.1 or 0.5 mg/kg. Blood samples were
collected via cardiac stick under isoflurane 90 minutes
after LPS injection. Serum separated from the blood sam-
ples was analyzed for TNFα, corticosterone, and ACTH.
RU486 in C57BL/6 DIO mice acutely challenged with 
lipopolysaccharide (LPS)
C57BL/6 DIO mice were mice with abnormal metabolism
resulted from over eating and high fat diet. This strain of
mice was used to simulate the effect of RU486 on LPS-
induced cytokine release in T2D subjects.
To determine the effect of RU486 on LPS-stimulated
cytokine production in animals with metabolic disorders,
one set of C57BL/6 DIO mice was orally treated with vehi-
cle or RU486 4, 20, 100 mg/kg. Thirty minutes later, the
mice were ip injected with LPS 0.1, 0.5 or 20 mg/kg. Blood
samples were collected via cardiac stick under isoflurane
90 minutes after LPS injection. Serum separated from the
blood samples was analyzed for TNFα, corticosterone,
and ACTH.
Bioassays
Serum TNF-α and IL-6 were measured using ELISA kits
(cat. # EMTNFA5 and EM2IL65 respectively) from Pierce
Biotechnology, Inc. (Rockford, IL). Serum MCP-1 and IL-
1β were measured using a customized MSD kit of Meso
Scale Diagnostic, LLC (Gaithersburg, MD). Serum corti-
costerone was measured using an ELISA kit OCTEIA Cor-
ticosterone (Ref. AC-14F1) of IDS Inc. (Fountain Hills,
AZ). Serum ACTH was measured using an ELISA kit ACTH
1–39 (cat. # S-1130) of Peninsula Laboratories, Inc (San
Carols, CA). Serum glucose, total cholesterol, and triglyc-
erides were measured with the Olympus Au640® clinical
chemistry analyzer (Serial #2040881, Olympus America
Inc, Diagnostic Systems Group, Two Corporate Center
Drive, Melville, NY). Blood HBA1c was measured with the
Bio-Rad Variant II Hemoglobin Analysis System (Bio-Rad
Diagnostics, Hercules California) utilizing the principles
of boronate affinity HPLC.BMC Pharmacology 2008, 8:7 http://www.biomedcentral.com/1471-2210/8/7
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Determination of PEPCK and G6Pase gene expression in 
liver of db/db mice by real time PCR
Total RNA in mouse liver was isolated by the TRIZOL®
method [39]. All RNA samples were DNased using the
DNA-free™ kit (Ambion, Austin, TX) according to the
manufacturer's protocol. The samples were then con-
verted to cDNA using the High Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA) according to proto-
col. PCR results were generated using the 5' nuclease assay
(TaqMan) [40] and the ABI 7900 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA). Primers and
probe for PEPCK are: Forward-TTGAACCTGAAAGGCCT-
GGG; Reverse-AAGGGAGGTCGGTGTTGACC; Probe-
CGTCAACGTGGAGGAGCTGTTTGGGAT. Primers and
probe for G6Pase are: Forward-CTGCATTGTGGCTTC-
CTTGG; Reverse-ATGCAAAGGGAACTGTTGCG; Probe-
GCCCCCATCCCAGGTTGAGTTGATCTT. The primers
and probe for Cyclophilin are: Forward-GGCCGATGAC-
GAGCCC; Reverse-TGTCTTTGGAACTTTGTCTGCAA;
Probe-TGGGCCGCGTCTCCTTCGA. The PCR cycling
conditions were 95°C for 10 minutes, and 40 cycles of
95°C for 15 seconds and 60°C for 1 minute.
Reagents
RU486 (Mifepristone, Cat. # M8046) and lipopolysaccha-
rides (LPS, Cat. # L3755, Batch # 046K4068) were pur-
chased from Sigma-Aldrich (St. Louis, MO).
Statistical analysis
There were 5–9 mice for each data point. Data are pre-
sented as mean ± SEM. Differences between each pair of
groups were analyzed with Student's t-test using JMP 6.0.0
software. A P value less than 0.05 was taken to be signifi-
cant.
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